Alnylam promotes Pushkal Garg to Chief R&D Officer; merges R&D functions

ALNYLAM PHARMACEUTICALS, INC.

Pushkal Garg appointed EVP, Chief Research and Development Officer to lead integrated R&D organization.
Kevin Fitzgerald's role expanded to include external innovation; receives one-time RSU grant of $2.5M.
Garg's base salary set at $825,000 with STI target of 65% of base; LTI target to be determined.
Fitzgerald's STI target increased to 60% of base salary.
Alnylam targets delivering RNAi therapeutics to all major tissues by 2030.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Pushkal Garg

Executive Vice President, Chief Research and Development Officer

ALNY · ALNYLAM PHARMACEUTICALS, INC.

Filed: June 18, 2025, 7:59 PM ET

the Committee approved (i) the appointment of Pushkal Garg, M.D., the Company’s current Chief Medical Officer, Executive Vice President, Development and Medical Affairs, to the position of Executive Vice President, Chief Research and Development Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Pushkal Garg was appointed as Executive Vice President, Chief Research and Development Officer at ALNYLAM PHARMACEUTICALS, INC..

Action: appointed
Role: Executive Vice President, Chief Research and Development Officer

Exact text from the filing

the Committee approved (i) the appointment of Pushkal Garg, M.D., the Company’s current Chief Medical Officer, Executive Vice President, Development and Medical Affairs, to the position of Executive Vice President, Chief Research and Development Officer

View on SEC.gov

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001178670-25-000076

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.